The Board of Directors of Celsense, Inc. unanimously elected Abby Lembersky to the Board effective February 10, 2021. Ms. Lembersky is the Director of Programs at City of Asylum. City of Asylum provides sanctuary to endangered literary writers, and presents over 175 free literary, arts, and cultural programs annually in a community setting to build social equity through cross-cultural exchange. Prior to joining City of Asylum in 2018, Ms. Lembersky worked in public programs at the Museum of Jewish Heritage in New York City and at Barnard College. Ms. Lembersky received an MBA from the Wisconsin School of Business at the University of Wisconsin-Madison.
Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. The company’s lead product Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense is the subject of a Drug Master File at US FDA and Health Canada, and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsense’s mission is to be the standard for cellular imaging in human health.
Information Contact: Charlie O’Hanlon, President and CEO of Celsense, Inc., (412) 263-2870 or firstname.lastname@example.org
Real-Time Results,<br />Faster and More Accurate
Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.
GET IN TOUCH
Send Us A Message
© 2020 Celsense, Inc. All rights reserved.